243 related articles for article (PubMed ID: 16485627)
1. The metabolic syndrome in women: a growing problem for cardiac risk.
Paul S; Smith L
J Cardiovasc Nurs; 2005; 20(6):427-32. PubMed ID: 16485627
[TBL] [Abstract][Full Text] [Related]
2. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention.
Osibogun O; Ogunmoroti O; Michos ED
Trends Cardiovasc Med; 2020 Oct; 30(7):399-404. PubMed ID: 31519403
[TBL] [Abstract][Full Text] [Related]
3. Interactions between obstructive sleep apnea and the metabolic syndrome.
Svatikova A; Wolk R; Gami AS; Pohanka M; Somers VK
Curr Diab Rep; 2005 Feb; 5(1):53-8. PubMed ID: 15663918
[TBL] [Abstract][Full Text] [Related]
4. Polycystic Ovarian Syndrome: Long-Term Health Consequences.
Zore T; Joshi NV; Lizneva D; Azziz R
Semin Reprod Med; 2017 May; 35(3):271-281. PubMed ID: 28658711
[No Abstract] [Full Text] [Related]
5. The metabolic syndrome: diagnosis and treatment.
Zieve FJ
Clin Cornerstone; 2004; 6 Suppl 3():S5-13. PubMed ID: 15707265
[TBL] [Abstract][Full Text] [Related]
6. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift.
Nolan CJ; Prentki M
Diab Vasc Dis Res; 2019 Mar; 16(2):118-127. PubMed ID: 30770030
[TBL] [Abstract][Full Text] [Related]
7. Polycystic Ovary Syndrome.
Azziz R
Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
[TBL] [Abstract][Full Text] [Related]
8. Metabolic syndrome and polycystic ovary syndrome... and vice versa.
Kandaraki E; Christakou C; Diamanti-Kandarakis E
Arq Bras Endocrinol Metabol; 2009 Mar; 53(2):227-37. PubMed ID: 19466215
[TBL] [Abstract][Full Text] [Related]
9. Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk.
Said S; Mukherjee D; Whayne TF
Curr Vasc Pharmacol; 2016; 14(5):415-425. PubMed ID: 27456105
[TBL] [Abstract][Full Text] [Related]
10. Polycystic ovary syndrome and metabolic syndrome.
Ali AT
Ceska Gynekol; 2015 Aug; 80(4):279-89. PubMed ID: 26265416
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of the insulin resistance syndrome.
Meigs JB
Curr Diab Rep; 2003 Feb; 3(1):73-9. PubMed ID: 12643149
[TBL] [Abstract][Full Text] [Related]
12. Managing mixed dyslipidemia in special populations.
Miller M
Prev Cardiol; 2010; 13(2):78-83. PubMed ID: 20377810
[TBL] [Abstract][Full Text] [Related]
13. Insulin resistance and polycystic ovary syndrome.
Ehrmann DA
Curr Diab Rep; 2002 Feb; 2(1):71-6. PubMed ID: 12643125
[TBL] [Abstract][Full Text] [Related]
14. Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome.
Cattrall FR; Healy DL
Best Pract Res Clin Obstet Gynaecol; 2004 Oct; 18(5):803-12. PubMed ID: 15380148
[TBL] [Abstract][Full Text] [Related]
15. Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis.
Zhu S; Zhang B; Jiang X; Li Z; Zhao S; Cui L; Chen ZJ
Fertil Steril; 2019 Jan; 111(1):168-177. PubMed ID: 30611404
[TBL] [Abstract][Full Text] [Related]
16. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women.
Alexander CJ; Tangchitnob EP; Lepor NE
Rev Cardiovasc Med; 2009; 10(2):83-90. PubMed ID: 19593320
[TBL] [Abstract][Full Text] [Related]
17. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease.
Baranova A; Tran TP; Birerdinc A; Younossi ZM
Aliment Pharmacol Ther; 2011 Apr; 33(7):801-14. PubMed ID: 21251033
[TBL] [Abstract][Full Text] [Related]
18. The pluripotential effects of hypolipidemic treatment for polycystic ovary syndrome (PCOS): dyslipidemia, cardiovascular risk factors and beyond.
Economou F; Xyrafis X; Christakou C; Diamanti-Kandarakis E
Curr Pharm Des; 2011; 17(9):908-21. PubMed ID: 21418035
[TBL] [Abstract][Full Text] [Related]
19. Cardiometabolic risks in polycystic ovary syndrome: long-term population-based follow-up study.
Behboudi-Gandevani S; Ramezani Tehrani F; Hosseinpanah F; Khalili D; Cheraghi L; Kazemijaliseh H; Azizi F
Fertil Steril; 2018 Dec; 110(7):1377-1386. PubMed ID: 30503137
[TBL] [Abstract][Full Text] [Related]
20. Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment.
Daskalopoulos G; Karkanaki A; Piouka A; Prapas N; Panidis D; Gkeleris P; Athyros VG
Curr Vasc Pharmacol; 2015; 13(6):788-800. PubMed ID: 25600030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
